Acivirax

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acivirax

Property Description
Active Ingredient Aciclovir (Acyclovir)
Pharmacological Class Antiviral, Antiherpetic agent
Origin Synthetic
Common Forms Tablet, Cream, Intravenous solution
High-Level Purpose Suppression of viral replication

What Type of Medicine is Acivirax (Aciclovir)?

Acivirax is a brand of a high-specificity synthetic pharmaceutical preparation classified as an antiviral drug, designated for managing infections caused by certain viruses, particularly those in the herpes family. Its core active component is Aciclovir (also known as Acyclovir), which is chemically defined as a purine nucleoside analogue. This places Acivirax firmly within the highly focused pharmacological class of antiherpetic agents.

Its primary purpose is to suppress the replication of the targeted viruses, a mechanism clinically recognized for efficacy in controlling outbreaks caused by the Herpes Simplex Virus and the Varicella Zoster Virus. Aciclovir is recognized on the Model List of Essential Medicines, confirming its fundamental therapeutic role globally. This medicine is primarily available as a prescription-only (Rx) product, reflecting its specific indication and mechanism of action.

Composition and Available Forms

The definitive constituent of Acivirax is the single active ingredient, Aciclovir, compounded as a single active ingredient product. Aciclovir works primarily by inhibiting DNA synthesis in the viral cell, which means the medication helps stop the virus from multiplying and spreading to other cells.

This active substance is supplied in multiple common dosage form(s) to allow for various routes of administration. These include the tablet and oral suspension for systemic absorption, as well as cream and ointment preparations intended for topical application in localized cases. The range of formulations is designed to address the unique needs of adult and pediatric patients encountering these specific viral challenges.

Regulatory References

  1. World Health Organization
  2. WHO Essential Medicines
  3. MedlinePlus

What side effects are possible with Acivirax?

Possible side effects and safety information

The safety profile of Acivirax (Aciclovir) is formally documented in regulatory texts, with adverse reactions categorized by their frequency and the physiological system they affect. The most common side effects reported in official labeling include headache, dizziness, and gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal pain. Skin reactions, including pruritus (itching) and rashes (sometimes associated with photosensitivity), are also listed as common.

Adverse events are formally grouped by System-Organ-Class, covering areas like the Nervous System and Gastrointestinal System. Rare and very rare events, which are still officially documented, involve more serious reactions across other systems. These include changes in the blood and lymphatic system (e.g., anemia, leukopenia), reversible increases in liver enzymes and creatinine, and potentially acute renal failure.

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies very rare but serious adverse reactions, such as anaphylaxis, angioedema, and severe neurological reactions (e.g., confusion, hallucinations, convulsions). These neurological events are generally reversible and are often associated with high doses or reduced kidney function.

Population-specific safety considerations are noted, particularly for older adults and individuals with renal impairment. These groups have an increased potential for toxicity, and official documents emphasize the need for adequate hydration during systemic therapy, especially during intravenous administration, to mitigate the risk of renal complications. The appearance of certain reactions may be linked to the speed of intravenous infusion or the patient's hydration status, as specified in official safety notes.

Overdose and Emergency Response

Acivirax overdose primarily affects the renal and central nervous systems, based on officially documented reports. Manifestations can include gastrointestinal symptoms such as nausea and vomiting, alongside pronounced neurological effects. Regulator-documented CNS symptoms range from confusion, agitation, and hallucinations to severe outcomes like seizures and coma.

A critical documented outcome of overdose is acute renal failure, which occurs due to the precipitation of Aciclovir when its solubility in the renal tubules is exceeded. This risk is notably elevated in elderly patients and individuals with impaired renal function. Overdose reports indicate that certain patient groups may be more susceptible to the severe neurological effects.

When to Seek Urgent Help

Regulatory agencies mandate seeking immediate medical attention if severe signs occur. Contact emergency services right away if a person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Treatment for an overdose is described as symptomatic and supportive. Regulatory documentation confirms that haemodialysis can be used to significantly accelerate the elimination of Aciclovir from the blood.

Therapeutic Uses of Acivirax

What Acivirax Treats: Main Uses and Benefits

Acivirax is used to manage conditions associated with symptoms that interfere with daily functioning, such as those caused by certain viral irritative states. It is applied across therapeutic domains involving heightened physiological activity linked to these symptoms, notably during episodes of shingles, chickenpox, and acute or recurrent manifestations of genital herpes and cold sores.

This medication is generally used to help with the symptomatic duration of the episode and supports the healing process of the sores. For patients experiencing frequent recurrences, Acivirax is commonly used as part of a long-term approach to manage the potential for future outbreaks.

“The medication helps address symptom clusters that may become intense or disruptive.”

Benefits and Symptom Relief

Acivirax provides symptomatic support in clinical settings that involve acute or unstable symptom patterns, and is relevant for easing the pain, burning, itching, and the discomfort associated with the formation of fluid-filled blisters. This approach helps maintain a sense of stability and contributes to improved day-to-day comfort.

Quick Fact: Support for Pain and Blistering Symptoms

The medication is helpful in situations where symptoms cluster into patterns requiring supportive management, assisting with maintaining functional stability when discomfort becomes more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Acivirax (Aciclovir) eligibility is defined by its official regulatory profile, which specifies populations who are contraindicated and groups who require restricted use.

Contraindications

Acivirax is absolutely contraindicated for patients with a documented history of hypersensitivity or allergic reaction to the active substance Aciclovir, to its prodrug Valaciclovir, or to any of the product’s inactive components.

Restricted and Conditional Use

Use is allowed in the following groups only under specific caution or mandatory adjustment, as the drug is primarily cleared by the kidneys:

  • Impaired Renal Function: Patients with kidney problems are eligible, but use is restricted and requires the dose to be reduced based on assessed renal function.
  • Older Adults (65 years): This group is eligible, but requires close monitoring and may need a dose adjustment due to the common age-related decline in kidney function.
  • Dehydrated Patients: Patients receiving systemic treatment must ensure adequate hydration to prevent potential drug accumulation in the kidneys.
  • Pregnancy and Lactation: Use during pregnancy is conditional; it is permitted only when a healthcare provider determines the clinical benefit justifies the potential unknown risk. The medicine passes into breast milk, necessitating careful risk assessment for the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acivirax (Aciclovir) interactions are strictly derived from official regulatory documentation, focusing on effects on drug clearance and additive risks, rather than therapeutic context or general safety.

Documented Pharmacokinetic Interactions

  • Exposure-Modifying Agents: Co-administration with certain medicinal products results in a documented pharmacokinetic interaction that increases the systemic exposure of Acivirax. This effect is specifically noted with agents such as Probenecid and Cimetidine, which reduce Acivirax renal clearance via competition for active tubular secretion. This leads to increased plasma concentrations (AUC and C max).
  • Mycophenolate Mofetil (MMF): Co-administration with MMF also results in increased concentrations of both products due to competitive inhibition of renal transport.

Documented Pharmacodynamic Interactions

  • Nephrotoxic Agents: A pharmacodynamic interaction exists when Acivirax is taken with other nephrotoxic agents. This combination is officially associated with an increased risk of renal impairment (nephrotoxicity). This risk is particularly noted as a constraint in patients who are dehydrated or have pre-existing renal compromise.

Ingestion Factors and Specific Populations

  • The official prescribing information states that the oral absorption of Acivirax is unaffected by food.
  • Interaction concerns have heightened significance for elderly patients and individuals with renal impairment, as their reduced kidney function can magnify the effects of any interaction that decreases drug clearance.

Mechanism of Action

The Mechanism of Selective Viral Replication Blockade

The action of Acivirax (Aciclovir) is fundamentally dependent on a selective two-step activation process. The inactive molecule must first be converted to its monophosphate form by the Viral Thymidine Kinase ( TK) , an enzyme expressed almost exclusively by actively multiplying herpes viruses ( HSV, VZV). This requirement ensures the drug is selectively concentrated and activated predominantly within virus-infected cells.

Once converted into the fully active Aciclovir triphosphate ( ACV-TP) by host kinases, the molecule directly targets the Viral DNA Polymerase. Acting as a dead-end substrate, ACV-TP is incorporated into the nascent viral DNA chain but lacks the necessary functional group for further elongation, resulting in obligate chain termination and inactivation of the enzyme. This molecular action immediately results in the cessation of viral genome replication, which in turn limits the formation of new viral particles.

This mechanism is constrained to periods of active replication. Since the latent virus residing in nerve ganglia does not express Viral TK, the drug cannot be activated and therefore does not apply to the dormant viral state.

Dosage and Administration Information

Acivirax is supplied in multiple official forms, including oral tablets, oral suspension, intravenous (IV) solutions, and topical creams, to allow for systemic or localized administration. The use of this medicine is defined by precise dosing schedules and administration protocols, which vary based on the targeted infection.

For systemic use, oral forms are typically administered on a regimen of two to five times daily. Specific schedules, such as 400 mg twice daily for chronic suppression or 800 mg five times daily for acute conditions like Herpes Zoster, are standardized for clinical use. Oral medication may be taken without regard to meals, but maintaining adequate hydration is a key procedural instruction for systemic therapy. Treatment is directed to begin as early as possible following symptom onset, such as during the prodrome phase.

When administered intravenously, the solution must be given via slow infusion over a period of at least one hour; rapid, bolus, or intramuscular injection is strictly prohibited to ensure correct delivery. The duration of therapy for acute episodes is formally defined, typically ranging from 5 to 10 days. Furthermore, the dose is adjusted for individuals with known renal impairment based on creatinine clearance, and this consideration is also applicable for older adults. Long-term suppressive use is subject to periodic review to determine the need for continued therapy.

Recent Clinical Evidence

Evidence for Use in Shingles (Herpes Zoster)

The evidence base for Acivirax relies on Randomized Controlled Trials (RCTs) that compare the medicine against a placebo or other antiviral treatments. Researchers monitored the time it takes for skin lesions to fully crust over and heal, which was a primary metric of the research. Studies also examined the duration of acute pain symptoms and the development of long-term pain, often known as post-herpetic neuralgia. Findings described patterns related to these outcomes measured over the defined short-term intervals. Data is limited for certain outcomes from studies directly comparing Acivirax to newer antiviral medications.


Evidence for Use in Chickenpox (Varicella)

Studies, primarily RCTs, monitored the timing of outcomes related to systemic imbalance, such as the time for fever to subside and the duration required for lesions to progress, primarily in children. Studies provided data concerning the recorded incidence of complications within the studied cohorts. Comparative evidence remains limited against non-drug management strategies for typical cases, and follow-up durations focused mainly on the acute illness phase.


Evidence for Use in Herpes Simplex

Acivirax was studied for both acute outbreaks (measuring healing time and symptom evolution) and long-term suppression (monitoring recurrence frequency). Research highlights changes measured in the time needed for lesions to heal and for acute symptoms to evolve. Research is ongoing to fully characterize viral resistance patterns and long-term patient-reported quality of life outcomes.


Evidence in Special Populations and Research Gaps

Research evaluated the medicine in pediatric patients (chickenpox), older adults (shingles), and those with compromised immune systems. Data for certain groups remain insufficient, such as for pregnant populations, and results apply only to the specific study populations. Research limitation frames include that comparative evidence is lacking for certain outcomes against newer agents, and research is still emerging for quality of life metrics over very extended observation periods.

Key Studies & References

  1. WHO Model List of Essential Medicines (23rd List, Aciclovir entry)

Frequently Asked Questions (FAQ)

Common questions about Acivirax (FAQ)

Q: How quickly should I expect Acivirax to start working?

According to official product information, after taking an oral dose, the highest measured concentration of the active ingredient in the bloodstream is typically reached within 1.5 to 2 hours. If multiple doses are prescribed, steady-state concentrations are usually achieved after one full day of dosing.

Q: What is the average duration of treatment with Acivirax?

The required duration of treatment is formally defined in official regulatory documents and is determined by the specific condition being treated. For acute viral episodes, the duration of therapy commonly ranges from 5 to 10 days.

Q: What if I miss a time I was supposed to take Acivirax?

Regulatory patient information states that a forgotten dose should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. In that case, the missed dose is generally advised to be skipped, and the regular schedule should be resumed. Official guidance indicates that taking a double dose to compensate for a missed one is not recommended.

Q: Can children take Acivirax?

Official documents describe specific dosage guidelines for use in children. These guidelines include recommendations for children aged two years and over, as well as separate considerations for children below the age of two years, dependent on the condition being addressed.

Q: Are there any specific dietary restrictions to be aware of while taking Acivirax?

Official prescribing information indicates that oral forms can be taken without regard to meals, and no specific dietary restrictions are described. However, regulatory guidance consistently advises maintaining adequate hydration by drinking plenty of fluids, particularly when taking the medicine by mouth or injection.

Q: Is it possible to develop a resistance to Acivirax over time?

Official information describes that resistance of the virus to the active ingredient can occur, usually due to changes in the viral enzymes. This possibility is noted for consideration in patients who show poor clinical response during the course of therapy.

Q: What should I do if Acivirax doesn't seem to be working for me?

Patient information generally advises consulting a healthcare professional if symptoms do not improve or if they worsen during the course of treatment. A healthcare professional can provide guidance based on the clinical response observed.

Q: What is the recommended approach if I have a persistent side effect from Acivirax?

Official guidance for persistent but non-serious side effects suggests consulting a healthcare professional or pharmacist. Consultation allows a healthcare provider to determine the next steps regarding the reaction and continued use.

Q: Do I need to finish the entire course of Acivirax even if I feel better?

Regulatory advice emphasizes the importance of completing the entire prescribed course of the medicine. This is because it is intended to help ensure the infection is completely treated and to potentially prevent the infection from becoming more difficult to treat.

Q: Is there a generic version of Acivirax available?

Yes, the active ingredient in Acivirax, Aciclovir (Acyclovir), is available as a generic prescription product. This means that versions from multiple manufacturers have been approved by regulatory bodies.

Q: Does Acivirax interact with common herbal supplements like St. John's Wort?

Official information indicates that data is insufficient to definitively state whether many herbal remedies or supplements, such as St. John’s Wort, can be safely combined with the drug. These products are not typically tested under the same strict regulatory conditions as prescription medicines.

Q: What kind of monitoring is typically involved when taking Acivirax?

Monitoring considerations are officially noted for patients with impaired kidney function and for older adults, often involving dose adjustment based on kidney function tests. Long-term suppressive therapy is also subject to periodic review by a healthcare provider.

Q: Does Acivirax contain any common allergens like lactose or gluten?

The inactive ingredients in Acivirax vary by the specific product form (tablet, capsule, suspension) and the manufacturer. Official product labeling provides a complete list of all inactive ingredients, which can be checked against specific allergen concerns.

Q: How does the effectiveness of Acivirax compare to placebo in clinical trials?

Official clinical trial summaries confirm that the medicine was studied against a placebo (an inactive substance). Findings indicated that the use of the drug in specific patient groups was associated with measurable changes in outcomes, such as a faster reduction in healing time or a decreased duration of symptoms.

Q: Can Acivirax be taken with flu or cold medications?

Official patient information notes that the active ingredients most commonly found in flu or cold medicines, such as acetaminophen and ibuprofen, are generally not listed as having documented pharmacokinetic interactions with this medicine.

Q: What should I do if I think I'm having an allergic reaction to Acivirax?

Regulatory documents list very rare but serious adverse reactions, such as anaphylaxis (severe allergic reaction). Official guidance indicates that immediate medical attention is sought if signs of a severe allergic reaction are observed.

Q: Can Acivirax be used during pregnancy or while breastfeeding?

Official guidelines state that use during pregnancy is conditional and is permitted only if a healthcare provider determines the clinical benefit justifies the potential unknown risk. The medicine passes into breast milk, and use during breastfeeding requires a careful risk assessment.

Q: Are there any common over-the-counter pain relievers that interact with Acivirax?

Official patient information notes often state that common over-the-counter pain relievers, such as acetaminophen and ibuprofen, are generally not listed as having documented pharmacokinetic interactions with this medicine.

Q: If I am taking vitamins or supplements, could they interact with Acivirax?

Regulatory guidance notes that information is insufficient to definitively determine the safety of combining the drug with many vitamins or herbal supplements, as these products are not typically tested under the same conditions as prescription medicines.

Q: If I have a known allergy to similar drugs, can I still use Acivirax?

The only absolute contraindication formally described in regulatory documents is a documented history of hypersensitivity or allergic reaction to the active ingredient, Aciclovir, its prodrug, Valaciclovir, or any of the product's inactive components.

Q: Can I continue to take my routine prescription medications while on Acivirax?

Official drug interaction documents only identify specific agents (e.g., Probenecid, Cimetidine, nephrotoxic agents) that are described as causing a pharmacokinetic interaction. For all other routine prescription medications, no change in drug exposure is officially noted.

Q: How long does Acivirax stay in your system after stopping treatment?

In adults with normal kidney function, the plasma half-life of the active ingredient, which is the time it takes for half of the drug to be eliminated from the bloodstream, is formally documented as being approximately 3.3 hours.

Q: What happens if I stop taking Acivirax suddenly?

Official warnings advise against stopping the medicine before completing the prescribed course. Stopping early is associated with warnings that the infection may not be fully treated or potentially making it more difficult to treat.

Q: Can I crush or split Acivirax tablets if I have trouble swallowing them?

Patient information for the oral tablet form describes that the tablet may be dissolved in a small amount of water to aid administration. Specific preparation instructions are described in the patient information to ensure the full dose is received when the tablet is altered from its solid form.

Q: Can Acivirax cause stomach upset, and if so, how is that managed?

Official documents list gastrointestinal effects, such as nausea, vomiting, and diarrhea, as common side effects. Patient information suggests descriptive measures to manage these effects, such as avoiding rich or spicy food or taking the medicine after having eaten.

Q: Is it described in official sources that Acivirax can cause sun sensitivity?

Official prescribing information lists a photosensitive rash as a reported adverse reaction. Patient guidance often notes that the skin may become sensitive to sunlight during treatment.

How should Acivirax be stored and disposed of?

Storage and Disposal Requirements for Acivirax (Acyclovir)

Acivirax must be stored under specific conditions to maintain its labeled quality and efficacy. All storage and disposal instructions are based strictly on official regulatory guidance.


Storage Conditions

Condition Requirement (Official Labeling)
Temperature Store tablets, capsules, and suspension at controlled room temperature, typically 20 C to 25 C.
Protection Keep protected from moisture; keep the container tightly closed and in its original container.
Prohibited Environment Acyclovir oral suspension must not be refrigerated and must not be frozen.
Child Safety Keep the medicine out of the reach and sight of children.

Disposal

Do not dispose of unused or expired Acivirax through household wastewater or general trash. Regulatory guidance mandates that disposal must be carried out according to local requirements, typically by returning the product to a pharmacy or a designated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acivirax found in:

A-Z Index: